Health · Pharma & Biotech · 2 hrs ago
J&J starts phase 3 trials of combination therapy for Crohn’s and colitis
Johnson & Johnson has begun phase 3 research on an experimental treatment for Crohn’s disease and ulcerative colitis.
The therapy, called JNJ-4804, combines guselkumab and golimumab in one injection.
It is aimed at people whose inflammatory bowel disease is no longer controlled by other medicines.
The drugs act on different processes linked to inflammation, and the company hopes their combined effect will work better than either alone.
Studies so far found no additional safety risk compared with using the drugs separately, but the company says more evidence is needed.
Long-term follow-up is still underway to show how long the treatment’s effects last.
The phase 3 research will help assess whether the combination can control inflammation and produce lasting benefits.
Johnson & Johnson has started phase 3 clinical research on JNJ-4804, an experimental combination therapy for Crohn’s disease and ulcerative colitis.
The therapy combines guselkumab and golimumab in a single injection.
The company is targeting patients who have stopped responding to available treatments or have not gained control of their disease with other options.
Earlier studies evaluated the combination in patients with ulcerative colitis and Crohn’s disease.
J&J says a key challenge is showing that combining the medicines does not compromise patient safety.
- Who
- Johnson & Johnson is developing the therapy for patients with Crohn’s disease and ulcerative colitis.
- What
- The company has started phase 3 research on JNJ-4804, a combination of guselkumab and golimumab.
- When
- The phase 3 research has started. The article was published on November 6, 2026.
- Where
- Not stated.
- Why
- The therapy is intended for patients who stop responding to treatments or have not been able to control their disease with other options.
This story does not have two clearly opposing sides.
The VEGA study tested the combination in patients with ulcerative colitis.
The DUET studies evaluated the therapy in patients with ulcerative colitis and Crohn’s disease.
J&J started phase 3 clinical research on JNJ-4804.
- Experimental therapy
- JNJ-4804
- Medicines combined
- Guselkumab and golimumab
- Form
- One injection
- Research stage
- Phase 3 clinical research started
- Diseases studied
- Crohn’s disease and ulcerative colitis
What people are saying
When treating patients with a single medicine, you reach a certain level of efficacy and nothing seems to surpass it until treatments are combined.
You’re not simply looking for one plus one, you’re looking for one plus one equals five, or at least equals three. You want to see the synergy.
Many patients with inflammatory bowel disease have had the condition for seven, eight or 10 years and have already tried several treatments.